Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:47:14.153Z.
Calculation as of: 2026-10-06T21:47:14.153Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2df09dd0ed9c1c1ce3105b02e8ae50a0cdbf9b2118b3d67a1d250f1ffe9c40c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-05-14.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
EV/EBIT RATIO AVG TTM
N/A
EV/EBIT RATIO AVG 3Y
N/A
EV/EBIT RATIO AVG 5Y
N/A
EV/EBIT RATIO AVG 10Y
N/A
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$216.91M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.07M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.24M
EV/EBIT Ratio
17.39x
TTM Avg
25.81x
3Y Avg
146.27x
5Y Avg
146.27x
Market Cap
$225.24M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.41M
EV/EBIT Ratio
N/A
TTM Avg
23.42x
3Y Avg
23.28x
5Y Avg
23.28x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $218.30M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | N/A | N/A | N/A | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 17.39x | 25.81x | 146.27x | 146.27x |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | N/A | 23.42x | 23.28x | 23.28x |
| Compugen Ltd. (CGEN)vs › | $209.91M | 6.69x | 6.24x | 9.86x | 9.86x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-05-14 | 0.42x |
| 2026-05-13 | 0.82x |
| 2026-05-12 | 0.69x |
| 2026-05-11 | 0.83x |
| 2026-05-08 | 0.85x |
| 2026-05-07 | 0.68x |
| 2026-05-06 | 0.74x |
| 2026-05-05 | 0.73x |
| 2026-05-04 | 0.71x |
| 2026-05-01 | 0.62x |
| 2026-04-30 | 0.47x |
| 2026-04-29 | 0.46x |
| 2026-04-28 | 0.57x |
| 2026-04-27 | 0.43x |
| 2026-04-24 | 0.63x |
| 2026-04-23 | 0.65x |
| 2026-04-22 | 0.60x |
| 2026-04-21 | 0.55x |
| 2026-04-20 | 0.69x |
| 2026-04-17 | 0.69x |
| 2026-04-16 | 0.71x |
| 2026-04-15 | 0.71x |
| 2026-04-14 | 0.65x |
| 2026-04-13 | 0.48x |
| 2026-04-10 | 0.51x |
| 2026-04-09 | 1.02x |
| 2026-04-08 | 1.05x |
| 2026-04-07 | 0.92x |
| 2026-04-06 | 0.77x |
| 2026-04-02 | 0.83x |
| 2026-04-01 | 0.70x |
| 2026-03-31 | 0.44x |
| 2026-03-30 | 0.30x |
| 2026-03-27 | 0.27x |
| 2026-03-26 | 0.46x |
| 2026-03-25 | 0.56x |
| 2026-03-24 | 0.42x |
| 2026-03-23 | 0.52x |
| 2026-03-20 | 0.41x |
| 2026-03-19 | 0.47x |
| 2026-03-18 | 0.40x |
| 2026-03-17 | 0.56x |
| 2026-03-16 | 0.44x |
| 2026-03-13 | 0.43x |
| 2026-03-12 | 0.42x |
| 2026-03-11 | 0.53x |
| 2026-03-10 | 0.66x |
| 2026-03-09 | 0.56x |
| 2026-03-06 | 0.54x |
| 2026-03-05 | 0.71x |
| 2026-02-11 | 0.37x |
| 2026-02-10 | 0.47x |
| 2026-02-09 | 0.83x |
| 2026-02-06 | 0.87x |
| 2026-02-05 | 0.56x |
| 2026-02-04 | 1.31x |
| 2026-02-03 | 1.70x |
| 2026-02-02 | 1.64x |
| 2026-01-30 | 1.18x |
| 2026-01-29 | 1.26x |
| 2026-01-28 | 1.11x |
| 2026-01-27 | 1.55x |
| 2026-01-26 | 1.98x |
| 2026-01-23 | 2.38x |
| 2026-01-22 | 2.63x |
| 2026-01-21 | 2.22x |
| 2026-01-20 | 1.67x |
| 2026-01-16 | 2.07x |
| 2026-01-15 | 2.44x |
| 2026-01-14 | 2.69x |
| 2026-01-13 | 2.66x |
| 2026-01-12 | 2.09x |
| 2026-01-09 | 2.38x |
| 2026-01-08 | 1.81x |
| 2026-01-07 | 1.79x |
| 2026-01-06 | 1.07x |
| 2026-01-05 | 1.19x |
| 2026-01-02 | 1.77x |
| 2025-12-31 | 3.47x |
| 2025-12-30 | 3.38x |
| 2025-12-29 | 3.72x |
| 2025-12-26 | 4.09x |
| 2025-12-24 | 4.40x |
| 2025-12-23 | 4.42x |
| 2025-12-22 | 4.38x |
| 2025-12-19 | 3.37x |
| 2025-12-18 | 3.25x |
| 2025-12-17 | 3.90x |
| 2025-12-16 | 4.56x |
| 2025-12-15 | 4.28x |
| 2025-12-12 | 4.54x |
| 2025-12-11 | 4.71x |
| 2025-12-10 | 4.85x |
| 2025-12-09 | 4.56x |
| 2025-12-08 | 4.36x |
| 2025-12-05 | 4.71x |
| 2025-12-04 | 3.38x |
| 2025-12-03 | 1.36x |
| 2025-12-02 | 0.18x |
| 2025-12-01 | 0.50x |
| 2025-11-28 | 0.78x |
| 2025-11-26 | 0.80x |
| 2025-11-25 | 0.63x |
| 2025-11-24 | 0.34x |
| 2025-11-21 | 0.70x |
| 2025-11-20 | 0.17x |
| 2025-11-19 | 0.20x |
| 2025-11-18 | 0.85x |
| 2025-11-17 | 0.68x |
| 2025-11-14 | 0.58x |
| 2025-11-13 | 0.61x |
| 2025-11-12 | 0.77x |
| 2025-11-11 | 0.24x |
| 2025-11-10 | 0.37x |
